Shuo Sun

Shuo Sun

Auto-generated profile, based on publicly available information

Shuo Sun

Department of Neurosurgery, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
SSShuo Sun
Shuo Sun
SQShiyu Qian
Shiyu Qian
RWRan Wang
Ran Wang
MZMengya Zhao
Mengya Zhao
RLRan Li
Ran Li
HLHongyi Liu
Hongyi Liu
Radiotherapy (RT) has been the standard-of-care treatment for patients with glioblastoma (GBM); however, the clinical effectiveness is hindered by therapeutic resistance. Here, we demonstrated that the tumor immune microenvironment (TIME) exhibited immunosuppressive properties and high expression of Golgi phosphoprotein 3 like (GOLPH3L) in RT-resistant GBM. Our study showed that GOLPH3L interacted with stimulator of interferon genes (STING) at the aspartic acid residue 184 in Golgi after RT, leading to coat protein complex II–mediated retrograde transport of STING from Golgi to endoplasmic reticulum. This suppressed the STING–NOD-like receptor thermal protein domain associated protein 3 (NLRP3)–mediated pyroptosis, resulting in suppressive TIME, driving GBM resistance to RT. Genetic GOLPH3L ablation in RT-resistant GBM cells augmented antitumor immunity and overcame tumor resistance to RT. Moreover, we have identified a small molecular inhibitor of GOLPH3L, vitamin B5 calcium (VB5), which improved the therapeutic efficacy of RT and immune checkpoint blockade by inducing a robust antitumor immune response in mouse models. Clinically, patients with GBM treated with VB5 exhibited improved responses to RT. Thus, reprogramming the TIME by targeting GOLPH3L may offer a potential opportunity to improve RT in GBM.